Value of the Multibiomarker Disease Activity Score to Predict Remission in RA: What Does the Evidence Show?

REFERENCES

1. 1.↵
   1. Felson DT,
   2. Smolen JS,
   3. Wells G,
   4. Zhang B,
   5. van Tuyl LH,
   6. Funovits J,
   7. et al.

   American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573–86.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Fleischmann R,
   2. Schiff M,
   3. Weinblatt ME,
   4. Maldonado M,
   5. Massarotti E,
   6. Yazici Y

   . Two-year results from the Ample Trial: Low disease activity and association between remission and changes in physical function and radiographic outcomes with subcutaneous abatacept or adalimumab. Arthritis Rheum 2013;65 Suppl 10:S209.

   OpenUrl
3. 3.↵
   1. Centola M,
   2. Cavet G,
   3. Shen Y,
   4. Ramanujan S,
   5. Knowlton N,
   6. Swan KA,
   7. et al.

   Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One 2013;8:e60635.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Curtis JR,
   2. van der Helm A,
   3. van Mil AH,
   4. Knevel R,
   5. Huizinga TW,
   6. Haney DJ,
   7. et al.

   Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res 2012;64:1794–803.

   OpenUrlCrossRef
5. 5.↵
   1. Fleischmann R,
   2. van der Heijde D,
   3. Koenig AS,
   4. Pedersen R,
   5. Szumski A,
   6. Marshall L,
   7. et al.

   How much does disease activity score in 28 joints ESR and CRP calculations underestimate disease activity compared with the simple disease activity index? Ann Rheum Dis 2015;74:1132–7.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Brahe CH,
   2. Østergaard M,
   3. Johansen JS,
   4. Defranoux N,
   5. Wang X,
   6. Bolce R

   . Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial. Scand J Rheumatol 2018 Jul 9 (E-pub ahead of print).
7. 7.↵
   1. Ghiti-Moghadam M,
   2. Lamers-Karnebeek FBG,
   3. Vonkeman HE,
   4. Ten Klooster PM,
   5. Tekstra J,
   6. Schilder AM

   . Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. PLoS One 2018;13:e0192425.

   OpenUrl
8. 8.↵
   1. Li W,
   2. Sasso EH,
   3. van der Helm-van Mil AH,
   4. Huizinga TW

   . Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. Rheumatology 2016;55:357–66.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Bouman CAM,
   2. van der Maas A,
   3. van Herwaarden N,
   4. Sasso EH,
   5. van den Hoogen FHJ,
   6. den Broeder AA

   . A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. Rheumatology 2017;56:973–80.

   OpenUrl
10. 10.↵
    1. Bechman K,
    2. Tweehuysen L,
    3. Garrood T,
    4. Scott DL,
    5. Cope AP,
    6. Galloway JB,
    7. et al.

    Flares in rheumatoid arthritis patients with low disease activity: predictability and association with worse clinical outcomes. J Rheumatol 2018 Sep 1 (E-pub ahead of print).
11. 11.↵
    1. Fleischmann R,
    2. Connolly SE,
    3. Maldonado MA,
    4. Schiff M

    . Brief report: estimating disease activity using multi-biomarker disease activity scores in rheumatoid arthritis patients treated with abatacept or adalimumab. Arthritis Rheumatol 2016;68:2083–9.

    OpenUrl
12. 12.↵
    1. Haschka J,
    2. Englbrecht M,
    3. Hueber AJ,
    4. Manger B,
    5. Kleyer A,
    6. Reiser M,
    7. et al.

    Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 2016;75:45–51.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Rech J,
    2. Hueber AJ,
    3. Finzel S,
    4. Englbrecht M,
    5. Haschka J,
    6. Manger B,
    7. et al.

    Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis 2016;75:1637–44.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Hagen M,
    2. Englbrecht M,
    3. Haschka J,
    4. Reiser M,
    5. Kleyer A,
    6. Hueber A,
    7. et al.

    Cost-effective tapering algorithm in patients with rheumatoid arthritis — combination of multibiomarker disease activity score and autoantibody status. J Rheumatol 2019;46:460–6.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Wu N,
    2. Lee YC,
    3. Shah N,
    4. Harrison DJ

    . Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study. Clinical Ther 2014;36:1231–41.

    OpenUrl